0.74
0.0893 (13.72%)
0.0893 (13.72%)
Upgrade to Real-Time
Afterhours (Closed)
| Volume | 236,164 |
|
|||||
| News | - | ||||||
| Day High | 0.76 | Low High |
|||||
| Day Low | 0.66 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Vaccinex Inc | VCNX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.0893 | 13.72% | 0.74 | 17:10:06 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.68 | 0.66 | 0.76 | 0.7395 | 0.6507 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 475 | 236,164 | $ 0.7257378 | $ 171,393 | - | 0.41 - 2.28 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:26:08 | 1 | $ 0.7236 | USD |
Period:
Draw Mode:
Vaccinex Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 36.91M | 49.88M | 30.20M | $ 900.00k | $ - | -0.79 | -1.30 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 5.55M | 0.70% |
Vaccinex News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VCNX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.50 | 0.76 | 0.447 | 0.5454385 | 113,220 | 0.24 | 48.0% |
| 1 Month | 0.55 | 0.76 | 0.41 | 0.5336236 | 58,068 | 0.19 | 34.55% |
| 3 Months | 0.73 | 0.8266 | 0.41 | 0.5713243 | 68,003 | 0.01 | 1.37% |
| 6 Months | 1.37 | 1.50 | 0.41 | 0.9119739 | 104,094 | -0.63 | -45.99% |
| 1 Year | 1.41 | 2.28 | 0.41 | 1.23 | 400,316 | -0.67 | -47.52% |
| 3 Years | 4.97 | 12.23 | 0.41 | 3.76 | 811,703 | -4.23 | -85.11% |
| 5 Years | 12.00 | 12.23 | 0.41 | 3.79 | 571,009 | -11.26 | -93.83% |
Vaccinex Description
| Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb. The firm generates revenue from collaborative research, license, development and commercialization agreements. |